Core Insights - InflaRx N.V. has conducted multiple data analyses of its Phase 3 study for vilobelimab in pyoderma gangrenosum (PG), which was terminated due to futility as recommended by the Independent Data Monitoring Committee (IDMC) [1][7] Study Overview - The Phase 3 study enrolled 54 patients, with 30 completing 6 months of treatment. The primary endpoint of complete target ulcer closure showed a difference of 20.8% for vilobelimab versus 16.7% for placebo, though this was not statistically significant [3] - Key secondary endpoints indicated improvement for vilobelimab, including complete disease remission (20.8% vs. 5.6%, p=NS) and >50% reduction in target ulcer volume at week 26 (36.4% vs. 16.7%, p=NS) [3] Efficacy Signals - Post-hoc analyses revealed an overall treatment effect with vilobelimab, showing an average percent change in target ulcer volume of -45.4% (p=0.0428) from Weeks 2 to 26 [4] - Significant treatment differences were noted from Week 14 (-57.6%, p=0.0357) to Week 26 (-63.2%, p=0.0122) for vilobelimab compared to placebo [4] Tolerability and Safety - Vilobelimab was well tolerated, with treatment-emergent adverse events (TEAEs) mostly mild to moderate. Serious related TEAEs were reported at 6.3% in the vilobelimab arm and 4.5% in the placebo arm [3] Future Development Plans - InflaRx plans to meet with the FDA to discuss potential development pathways for vilobelimab in PG, which may involve collaboration with a partner [7][9] - The company is prioritizing the development of izicopan (INF904) and does not expect to allocate significant resources towards vilobelimab's development independently [9] Company Background - InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics, utilizing proprietary technologies to develop inhibitors of the complement activation factor C5a and its receptor [11] - Vilobelimab is a first-in-class monoclonal antibody targeting C5a, demonstrating disease-modifying clinical activity in various studies [10]